Key Highlights
- Tempus AI and Remix Therapeutics expand their strategic alliance.
- Remix utilizes Tempus’ multimodal data to advance REM-422 in Phase I trials.
- Next-generation sequencing support provided by Tempus for clinical trials.
- Focus on Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) cohorts.
Source: Business Wire
Notable Quotes
- “Tempus’ multimodal data, analytics, and sequencing support will be invaluable tools as we advance our lead candidate, REM-422, into the clinic.” — Dominic Reynolds, Ph.D., Chief Scientific Officer at Remix
- “We’re excited to work with a biotech like Remix that understands and embraces the value that Tempus’ multimodal data can bring to their important work.” — Ryan Fukushima, Chief Operating Officer at Tempus
SoHC's Take
The expanded collaboration between Tempus AI and Remix Therapeutics represents a significant advancement in the field of precision medicine. By integrating Tempus’ comprehensive data analytics and sequencing capabilities, Remix is well-positioned to accelerate the development of their novel RNA-modulating therapies. This partnership highlights the growing importance of leveraging AI and multimodal data to facilitate the discovery and development of targeted treatments, particularly for challenging conditions such as Adenoid Cystic Carcinoma and Acute Myeloid Leukemia. As the biotechnology landscape continues to evolve, such strategic alliances will be crucial in driving innovation and improving patient outcomes.
